| 生长抑素受体介导放射性核素治疗神经内分泌肿瘤的临床研究进展 |
| |
| 引用本文： | 彭伟皑,匡安仁. 生长抑素受体介导放射性核素治疗神经内分泌肿瘤的临床研究进展[J]. 同位素, 2005, 18(3): 173-177 |
| |
| 作者姓名： | 彭伟皑 匡安仁 |
| |
| 作者单位： | 四川大学华西医院核医学科,四川,成都,610041 |
| |
| 摘 要： | 已进入临床应用的放射性核素标记生长抑素类似物有^111In-奥曲肽、^90Y-奥曲肽、^177Lu-奥曲肽和^90Y-兰瑞肽。这些药物与神经内分泌肿瘤过度表达的生长抑素受体（Somatostatin Receptor，SSTR）相结合，起到内照射和化疗的双重治疗作用。已有的研究表明，SSTR介导的放射性核素治疗神经内分泌肿瘤疗效较好，且无严重的毒副作用，是一种有发展前景的神经内分泌肿瘤的治疗方法。^177Lu-奥曲肽和^90Y-兰瑞肽的疗效更好，完全缓解和部分缓解率可达40％以上，稳定状态高达45％。
|
| 关 键 词： | 放射性核素 生长抑素 神经内分泌肿瘤 临床研究 疗效 |
| 文章编号： | 1000-7512（2005）03-0173-05 |
| 收稿时间： | 2004-05-26 |
| 修稿时间： | 2004-09-13 |
New Advances of Somatostatin Receptor-targeted Radionuclide Therapy for Neuroendocrine Tumors |
| |
| PENG Wei-ai,KUANG An-ren. New Advances of Somatostatin Receptor-targeted Radionuclide Therapy for Neuroendocrine Tumors[J]. Isotopes, 2005, 18(3): 173-177 |
| |
| Authors: | PENG Wei-ai KUANG An-ren |
| |
| Affiliation: | Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China |
| |
| Abstract: | Radiolabeled Somatostatin Analogues in clinical applications include ()~(111)In-Pentetreotide,()~(90)Y-DOTATOC,()~(177)Lu-octreotate and()~(90)Y-DOTALAN,After these radiopharmacies bind with SSTR2s which are overexpressed on the cell membrane,they can produce both chemotherapy and radiotherapy effects on neuroendocrine tumors.The researches indicat that SRTRT(Somatostatin Receptor-targeted Radionuclide Therapy) is a promising treatment for neuroendocrine tumors because of its better curative effect,less side effect and less toxicity.The curative effect of()~(177)Lu-octreotate and ()~(90)Y-DOTALAN is better than that of()~(111)In-pentetreotide and()~(90)Y-DOTATOC,the rate of complete remission and partial remission is above 40% and the rate of stable disease is 45%. |
| |
| Keywords: | neuroendocrine tumors radionuclide therapy somatostatin receptor(SSTR) octreotide lanreotide |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
